• PDF / 169,765 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 26 Downloads / 122 Views

DOWNLOAD

REPORT

---

1 S

Daclatasvir/sofosbuvir Virologic failure due to development of drug resistance in hepatitis C virus infection: 2 case reports

In a retrospective comparative study conducted from 2010–2019, two patients [ages and sexes not stated] were described, who experienced virologic failure due to development of drug resistance during treatment with sofosbuvir and daclatasvir for hepatitis C virus (HCV) infection. The patients, who had HCV genotype 1 or 3 infection, follicular lymphoma and liver cirrhosis, started receiving antiviral therapy with sofosbuvir and daclatasvir for 12 weeks [dosages and routes not stated]. Five days later, they received immunochemotherapy with R-CHOP regimen comprising rituximab, doxorubicin, cyclophosphamide, vincristine and prednisone. Additionally, ribavirin was administered for liver cirrhosis. The patients completed 12 weeks of sofosbuvir and daclatasvir therapy, and achieved a sustained virologic response. However, 12 weeks post-treatment, both the patients experienced virologic failure (relapse). The genotypic drug-resistance analysis revealed Y93H resistance-associated substitutions in non-structural 5A region of HCV, associated with a low treatment response. The findings suggested virologic failure due to development of sofosbuvir and daclatasvir resistance in both the patients. Due to HBV coinfection, entecavir prophylaxis was initiated. One patient was successfully retreated with another antiviral regimen, while the other patient died due to follicular lymphoma progression. Nesterova E, et al. Safe and effective treatment of follicular lymphoma in patients with HCV-infection. Hematological Oncology 38: 604-606, No. 4, Oct 2020. Available 803518885 from: URL: http://doi.org/10.1002/hon.2751

0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 5 Dec 2020 No. 1833